RealFeedApp New melanoma vaccine outperforms scientists' expectations
A phase 3 clinical trial confirmed the efficacy of the world's first personalized mRNA vaccine against melanoma. Results presented at the 2026 European Society for Medical Oncology Congress and set for publication in the New England Journal of Medicine exceed researchers' expectations.
- Field
- cancer research
- What they did
- Scientists conducted a phase 3 clinical trial of a personalized mRNA cancer vaccine against melanoma, which reduced the risk of recurrence or death by 42 percent compared to standard immunotherapy alone.
- Why it matters
- These results exceed scientists' expectations and could represent a foundational shift in cancer treatment by harnessing the immune system in a more personalized way.
#melanoma#mrna vaccine#phase 3 trial#immunotherapy#cancer prevention
